These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 14739125)

  • 21. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency.
    Moriyama Y; Okamura T; Inazu A; Doi M; Iso H; Mouri Y; Ishikawa Y; Suzuki H; Iida M; Koizumi J; Mabuchi H; Komachi Y
    Prev Med; 1998; 27(5 Pt 1):659-67. PubMed ID: 9808796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians.
    Forrester JS; Makkar R; Shah PK
    Circulation; 2005 Apr; 111(14):1847-54. PubMed ID: 15824213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein.
    Hiraoka H; Yamashita S; Matsuzawa Y; Kubo M; Nozaki S; Sakai N; Hirano K; Kawata S; Tarui S
    Hepatology; 1993 Jul; 18(1):103-10. PubMed ID: 8325601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic, pharmacodynamic, and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjects.
    Wolk R; Chen D; Clark RW; Mancuso J; Barclay PL
    Clin Pharmacol Ther; 2009 Oct; 86(4):430-7. PubMed ID: 19587642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microsomal enzyme inducers raise plasma high-density lipoprotein cholesterol levels in healthy control subjects but not in patients with primary hypoalphalipoproteinemia.
    Franceschini G; Werba JP; D'Acquarica AL; Gianfranceschi G; Michelagnoli S; Sirtori CR
    Clin Pharmacol Ther; 1995 Apr; 57(4):434-40. PubMed ID: 7712672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.
    Okamoto H; Yonemori F; Wakitani K; Minowa T; Maeda K; Shinkai H
    Nature; 2000 Jul; 406(6792):203-7. PubMed ID: 10910363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
    Brousseau ME; Diffenderfer MR; Millar JS; Nartsupha C; Asztalos BF; Welty FK; Wolfe ML; Rudling M; Björkhem I; Angelin B; Mancuso JP; Digenio AG; Rader DJ; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1057-64. PubMed ID: 15761191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Curr Opin Lipidol; 2006 Aug; 17(4):394-8. PubMed ID: 16832162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus.
    de Vries R; Borggreve SE; Dullaart RP
    Clin Lab; 2003; 49(11-12):601-13. PubMed ID: 14651331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction.
    Zeller M; Masson D; Farnier M; Lorgis L; Deckert V; Pais de Barros JP; Desrumaux C; Sicard P; Grober J; Blache D; Gambert P; Rochette L; Cottin Y; Lagrost L
    J Am Coll Cardiol; 2007 Nov; 50(20):1948-55. PubMed ID: 17996559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
    Kuivenhoven JA; de Grooth GJ; Kawamura H; Klerkx AH; Wilhelm F; Trip MD; Kastelein JJ
    Am J Cardiol; 2005 May; 95(9):1085-8. PubMed ID: 15842977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
    Ballantyne CM; Miller M; Niesor EJ; Burgess T; Kallend D; Stein EA
    Am Heart J; 2012 Mar; 163(3):515-21, 521.e1-3. PubMed ID: 22424025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CETP inhibition in cardiovascular risk management: a critical appraisal.
    Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
    Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells.
    Huang Z; Inazu A; Kawashiri MA; Nohara A; Higashikata T; Mabuchi H
    Am J Physiol Endocrinol Metab; 2003 Jun; 284(6):E1210-9. PubMed ID: 12604506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
    Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
    Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association of HDL cholesterol concentration with the -629C>A CETP promoter polymorphism is not fully explained by its relationship with plasma cholesteryl ester transfer.
    Dullaart RP; Borggreve SE; Hillege HL; Dallinga-Thie GM
    Scand J Clin Lab Invest; 2008; 68(2):99-105. PubMed ID: 17852818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.